- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02940756
Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo (TETRDC2016)
Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial
The Democratic Republic of the Congo (DRC) is among the countries most affected by malaria in Sub-Saharan Africa. Condidering its size and the geographic position, the DRC is meant to play a major role in the malaria control in the region. The National Malaria Control program recommends artemisinin-based combination treatments (ACTs), in particular artesunate-amodiaquine or artemether-lumefrantrine for the treatment of uncomplicated malaria. Previous studies indicated that ACTs are still effective, with efficacy above the required threshold of 90%. It is required to assess regularly the efficacy of antimalarial drugs, in order to ascertain the relevance of treatment guidelines such that, in case of increasing failure rates, alternative options can be decided ontime.
The purpose of this trial is to assess efficacy and safety of artesunate-amodiaquine (ASAQ Winthrop®), artemether-lumefantrine (Coartem Dispersible®) and dihydro-artemisinin-piperaquine (Eurartesim®) at day 42 in the treatment of uncomplicated Plasmodium falciparum malaria in six surveillance sites around DRC.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Equateur
-
Bolenge, Equateur, Congo, The Democratic Republic of the
- Centre de santé Bolenge
-
-
Haut-Katanga
-
Kapolowe, Haut-Katanga, Congo, The Democratic Republic of the
- Centre de santé Lupidi 1
-
-
Kasai Central
-
Kazumba, Kasai Central, Congo, The Democratic Republic of the
- Centre de Santé de Référence Mikalayi
-
-
Kongo Central
-
Kimpese, Kongo Central, Congo, The Democratic Republic of the
- Centre Evangélique de Coopération
-
-
Nord-Kivu
-
Rutshuru, Nord-Kivu, Congo, The Democratic Republic of the
- Centre de Santé de Référence Rutshuru
-
-
Tshopo
-
Kabondo, Tshopo, Congo, The Democratic Republic of the
- Centre de Santé Foyer Social
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- children aged 6 to 59 months
- axillary temperature ≥ 37.5 °C or history of fever during the 24 h before recruitment
- monoinfection with Plasmodium falciparum with asexual parasite count of 2,000 to 200,000/µL
- ability to swallow oral medication
- ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule
- informed consent from a parent/guardian
- absence of general danger signs or signs of severe falciparum malaria according to the definitions of WHO (2000)
- absence of severe malnutrition according to WHO child growth standards
- absence of febrile condition due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal or hepatic diseases, HIV/AIDS)
- absence of regular medication, which might interfere with antimalarial pharmacokinetics
- absence of history of hypersensitivity reactions or contraindication to any medicine being tested or used as alternative treatment
Exclusion Criteria:
- presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO
- body weight < 5kg
- hemoglobin level < 5g/ dL
- mixed or monoinfection with another Plasmodium species detected by microscopy
- presence of severe malnutrition
- presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS)
- regular medication, which may interfere with antimalarial pharmacokinetics;
- history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: artesunate-amodiaquine
Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
|
Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
Other Names:
|
Experimental: artemether-lumefantrine
Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk). One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days. |
Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk). One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days.
Other Names:
|
Experimental: Dihydroartemisinine-piperaquine
Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine.
Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
|
Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine.
Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PCR-adjusted efficacy
Time Frame: day 42
|
the proportion of children with PCR adequate clinical and parasitological response
|
day 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PCR-unadjusted efficacy
Time Frame: day 42
|
the proportion of children with treatment failure: all treatment failures detected during the follow-up, regardless of genotyping
|
day 42
|
K-13 propeller polymorphisms
Time Frame: day 42
|
the proportion of mutations in portions of P. falciparum gene encoding kelch(K-13)-propeller domains (confering resistance to artemisinin)
|
day 42
|
incidence of adverse events
Time Frame: day 42
|
monitoring of all adverse events experienced by participants
|
day 42
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gauthier Mesia Kahunu, PhD, University of Kinshasa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Lumefantrine
- Artemether
- Artesunate
- Artemether, Lumefantrine Drug Combination
- Piperaquine
- Amodiaquine
- Artenimol
Other Study ID Numbers
- ASAQ-LA-DHAPQP 2015 DRC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on artesunate-amodiaquine
-
Charite University, Berlin, GermanyKintampo Health Research Centre, Ghana; University for Development Studies,...Unknown
-
Heidelberg UniversityCompleted
-
London School of Hygiene and Tropical MedicineKintampo Health Research Centre, GhanaCompleted
-
SanofiCompletedMalariaCameroon, Madagascar, Mali, Senegal
-
SanofiCompleted
-
SanofiMedicines for Malaria VentureCompleted
-
Karolinska University HospitalSuspended
-
Centre MurazInstitute of Tropical Medicine, BelgiumCompletedUncomplicated MalariaBurkina Faso
-
Kwame Nkrumah University of Science and TechnologyDepartment for International Development, United Kingdom; Malaria Consortium... and other collaboratorsCompleted